52% C-Peptide Boost: Biomea Fusion's Icovamenib Shows Durable Phase 2 T1D Results
BMEA has more than doubled off its 52-week low of $0.872.
Summary
Biomea Fusion announced highly positive 52-week results from its Phase 2 COVALENT-112 trial for icovamenib in Type 1 Diabetes. The study demonstrated a significant 52% increase in mean C-peptide AUC at Week 12 (p < 0.001) in patients diagnosed within 3 years, with this improvement largely preserved through Week 52 after only a 12-week treatment period. This data is particularly compelling as such magnitude and durability are not typically observed in Type 1 Diabetes, representing a major de-risking event for the program. This positive development directly supports the company's strategic pivot to diabetes programs, as highlighted in its recent 10-K, and could significantly alleviate concerns regarding its going concern warning. The company plans to present a comprehensive dataset at the upcoming American Diabetes Association's Scientific Sessions in June and initiate a new Phase 2 trial in the second half of the year to explore extended dosing and combination therapies.
At the time of this announcement, BMEA was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.1M. The 52-week trading range was $0.87 to $3.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.